PET Imaging for Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Lung Cancer+1 MorePET Imaging - DiagnosticTest
Eligibility
18 - 80
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study if a new imaging agent is safe for use in patients with pulmonary fibrosis and if it can help detect collagen deposition.

Eligible Conditions
  • Lung Cancer
  • Pulmonary Fibrosis

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Up to 36 months

Two hours
Ability to detect increased collagen deposition in pulmonary fibrosis.
Up to 3 months
Ability of [68Ga]CBP8 to detect collagen deposition in areas of radiation injury.
Up to 36 months
Ability of the degree of collagen deposition to predict disease progression.

Trial Safety

Trial Design

3 Treatment Groups

Healthy Individuals
1 of 3
Pulmonary Fibrosis Subjects
1 of 3
Lung Cancer Subjects
1 of 3

Experimental Treatment

100 Total Participants · 3 Treatment Groups

Primary Treatment: PET Imaging · No Placebo Group · Phase 1

Healthy IndividualsExperimental Group · 2 Interventions: PET Imaging, [68Ga]CBP8 · Intervention Types: DiagnosticTest, Drug
Pulmonary Fibrosis SubjectsExperimental Group · 2 Interventions: PET Imaging, [68Ga]CBP8 · Intervention Types: DiagnosticTest, Drug
Lung Cancer SubjectsExperimental Group · 2 Interventions: PET Imaging, [68Ga]CBP8 · Intervention Types: DiagnosticTest, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PET Imaging
2008
Completed Phase 3
~370

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 36 months

Who is running the clinical trial?

National Heart, Lung, and Blood Institute (NHLBI)NIH
3,593 Previous Clinical Trials
46,945,746 Total Patients Enrolled
Massachusetts General HospitalLead Sponsor
2,703 Previous Clinical Trials
30,853,108 Total Patients Enrolled
Sydney B Montesi, MDPrincipal InvestigatorMassachusetts General Hospital

Eligibility Criteria

Age 18 - 80 · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Total enrollment for all groups will not exceed 100 subjects.
You must be at least 18 years of age to participate in this study.
You are deemed healthy at screening visit as determined by the physician investigator or nurse practitioner, based on the following assessments at Screening: physical examination, medical history, and vital signs.
References